Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      dsm-firmenich reports full year 2024 results


      News provided by

      dsm-firmenich

      13 Feb, 2025, 06:00 GMT


      This image opens in the lightbox
      View PDF
      dsm-firmenich
      This image opens in the lightbox
      dsm-firmenich logo (PRNewsfoto/dsm-firmenich)

      KAISERAUGST, Switzerland and MAASTRICHT, Netherlands, Feb. 13, 2025 /PRNewswire/ --

      Management Report

      2024 highlights

      • Strategic plan executed: leading, innovation-focused consumer company in nutrition, health & beauty established
      • Significant improvement of financial results, with strong organic sales growth and cash flow
      • Strong Q4 with continued good business momentum across all businesses
      • Ambitious climate targets set and externally validated by SBTi
      • Stable dividend of €2.50 proposed
      • €1 billion share buyback program to be launched
      • Outlook 2025: Adjusted EBITDA of at least €2.4 billion

      Key figures

      in € millions


      FY 2024

      Pro forma
      FY 2023¹

      % Change


      Q4 2024


      Q4 2023

      % Change

      Sales

      12,799

      12,310

      4

      3,257

      3,112

      5

      Organic sales growth (%)

      6



      7



      Adj. EBITDA

      2,118

      1,777

      19

      601

      439

      37

      Adj. EBITDA margin (%)

      16.5

      14.4


      18.5

      14.1


      Core adj. net profit

      849

      555

      53




      1 Represents the figures on a pro forma basis, including the Firmenich results as if the merger had occurred as of the beginning of the year. The pro forma figures represent the results from continuing operations - please also refer to the section Definitions.

      Key figures on an IFRS basis

      in € millions

      FY 2024

      FY 2023²

      % Change

      Sales

      12,799

      10,627

      20

      Net profit from continuing operations

      280

      (636)

      144

      Net profit (total group)

      280

      2,153

      (87)

      2 Represents the figures on an IFRS basis, including the Firmenich results as of the merger date May 8, 2023.

      Dimitri de Vreeze, CEO, commented: "I am proud that we have delivered on our commitments in 2024 and have firmly established ourselves as a leading innovation-focused consumer company in nutrition, health & beauty. We redefined our strategic course with the announcement of the separation of Animal Nutrition & Health and the tuning of our portfolio which is well-progressed with the sale of marine lipids, yeast extracts, our minority stake in Robertet, and our stake in the Feed Enzymes Alliance with Novonesis.

      At the same time, we delivered strongly improved financial results in all our businesses, benefitting from better business conditions, and supported by a €200 million Adjusted EBITDA contribution from the merger synergies and the vitamin transformation program. We were also successful in substantially improving our cash flow ahead of our mid-term target.

      These achievements, together with the ongoing good momentum in our end markets, lead us to a positive full year outlook for 2025, which includes around €200 million Adjusted EBITDA from further cost and revenue synergies, and the vitamin transformation program. With the confidence we have in our earnings growth potential and the strong balance sheet, we have decided to initiate a €1 billion share buyback program. Moving forward, we will continue to execute our strategic plan, including exiting Animal Nutrition & Health and fully focusing on growing our innovation-driven core activities. Hence, we are fully on-track to meet our mid-term ambitions."

      2025 Plan

      • Acceleration of innovation and creation-led organic sales growth
      • Delivery of further cost and sales synergies for about €100 million to Adjusted EBITDA
      • Completion of the vitamin transformation program, with a contribution of about €100 million to Adjusted EBITDA
      • Exiting Animal Nutrition & Health and finalizing the tuning of our portfolio as announced at the 2024 CMD
      • Strengthening our sustainability leadership for People and Planet

      Outlook 2025

      For the group, we estimate a full year Adjusted EBITDA of at least €2.4 billion, which includes at least €100 million contribution from the temporary vitamin price effect from a supply disruption in the vitamin market.

      Strategy

      At its capital markets day in Paris on June 3, 2024, dsm-firmenich defined its strategy to better leverage its unique portfolio and capabilities to further strengthen its position as a global leader in nutrition, health, and beauty, and maximising the synergy potential of the merger.

      The company is focusing on its consumer activities after having announced plans to separate the Animal Nutrition & Health business from the Group and after tuning the portfolio by deprioritizing certain activities, that contribute more than €600 million in annual sales. In 2024, the company sold two of these activities, representing about €300 million in annual sales, the yeast extract business to Lesaffre and the marine lipids activities to KD Pharma Group. In addition, the company sold its stake in Robertet for almost €400 million.

      With these strategic actions, the company wants to accelerate its innovation-led growth by prioritizing the high-growth and high-margin segments of Perfumery & Beauty (P&B), Taste, Texture & Health (TTH) and Health, Nutrition & Care (HNC), with the following mid-term financial targets for dsm-firmenich in its new scope:

      • Organic Sales Growth: 5-7%
      • Adjusted EBITDA margin: 22-23%
      • Cash-to-sales conversion: >10%

      Delivering synergies through integration

      dsm-firmenich is on track to achieve its target synergies contributing approximately €350 million to Adjusted EBITDA. Around half of this is expected to come from cost efficiencies. The other half of the synergies are expected from incremental revenues of €500 million driven by complementary capabilities and realized in all three business units of the Group's new scope: 60% in TTH, 25% in HNC and 15% in P&B. Since the merger, the company has realized over €120 million contribution to Adjusted EBITDA from synergies. In 2025, the company expects to realize a further contribution of around €100 million to Adjusted EBITDA.

      Vitamin transformation program

      Mid-2023, the company launched a program to reduce costs and restore profitability in its vitamin activities, expected to generate an estimated contribution to Adjusted EBITDA of around €200 million. These savings are incremental to the €350 million Adjusted EBITDA synergies target. 

      In 2024, the vitamin transformation program contributed around €100 million to Adjusted EBITDA. In 2025, the company expects to realize the remaining contribution of around €100 million to Adjusted EBITDA.

      Separation of Animal Nutrition & Health from the Group

      In February 2024, dsm-firmenich announced its intention to separate the Animal Nutrition & Health business from the company having concluded a different ownership structure would best realize its full potential. Furthermore, through this process, the company would reduce its exposure to vitamins earnings volatility and its capital intensity, in-line with its long-term strategy.

      On February 11, 2025, dsm-firmenich announced the sale of its stake in the Feed Enzymes Alliance to its equal partner, Novonesis for €1.5 billion. With the scope of the separation of the Animal Nutrition & Health business now defined, next week dsm-firmenich will begin the process of seeking transaction options to exit Animal Nutrition & Health, which is expected in the course of 2025.

      Stable dividend

      At the Annual General Meeting on May 6, 2025, the Board of Directors of dsm-firmenich will propose a cash dividend of €2.50 per share for the financial year 2024. Of this total dividend, €1.44 to be paid out of capital contribution reserves without deduction of any Swiss withholding tax. The remaining €1.06 to be paid out of available earnings and therefore subject to 35% Swiss withholding tax.

      New share buyback program

      dsm-firmenich intends to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital. This program is planned to start in Q2 2025 for an initial €500 million and will be increased to €1 billion upon the completion of the sale of dsm-firmenich's stake in the Feed Enzymes Alliance. This program is targeted to be completed by Q2 2026. The company remains committed to its strong investment grade credit ratings.

      Key figures and indicators

      in € millions


      FY 2024

      Pro forma
      FY 2023¹

      % Change


      Q4 2024


      Q4 2023

      % Change

      Net sales

      12,799

      12,310

      4

      3,257

      3,112

      5

      P&B

      3,964

      3,709

      7

      966

      914

      6

      TTH

      3,245

      3,038

      7

      790

      768

      3

      HNC

      2,214

      2,270

      (2)

      562

      581

      (3)

      ANH

      3,324

      3,227

      3

      930

      833

      12

      Corporate

      52

      66

      (21)

      9

      16

      (44)

      Adj. EBITDA 

      2,118

      1,777

      19

      601

      439

      37

      P&B

      882

      783

      13

      202

      192

      5

      TTH

      615

      556

      11

      144

      133

      8

      HNC

      371

      389

      (5)

      102

      94

      9

      ANH

      343

      128

      168

      176

      32

      450

      Corporate

      (93)

      (79)

      (18)

      (23)

      (12)

      (92)

      Adj. EBITDA margin (%)

      16.5

      14.4


      18.5

      14.1


      P&B

      22.3

      21.1


      20.9

      21.0


      TTH

      19.0

      18.3


      18.2

      17.3


      HNC

      16.8

      17.1


      18.1

      16.2


      ANH

      10.3

      4.0


      18.9

      3.8


      Adj. EBIT

      926

      666

      39











      Core adj. EBIT

      1,213

      850

      43




      Core adj. net profit

      849

      555

      53











      Average number of shares (x millions)

      264.6

      265.1





      Core adj. EPS

      3.10

      2.03












      (Avg.) core capital employed

      15,942

      16,423





      Core adj. ROCE (%)  

      7.6

      5.2












      Operating working capital

      3,603

      3,769²





      Capital expenditures (cash)

      764

      734





      Adj. gross operating free cash flow

      1,552

      999





      Sales to cash conversion %

      12.1

      8.1





      1 Represents the figures on a pro forma basis, including the Firmenich results as if the merger had occurred as of the beginning of the year. The pro forma figures represent the results from continuing operations - please also refer to the section Definitions.

      2 Restated for comparative purposes.

      Key figures and indicators on an IFRS basis

      in € millions

      FY 2024

      FY 2023³

      % Change

      Net sales

      12,799

      10,627

      20

      EBITDA

      1,991

      810

      146

      EBITDA margin (%)

      15.6

      7.6


      EBIT

      561

      (497)

      213

      Net profit (total group)

      280

      2,153


      Net EPS (total group)

      0.94

      9.14






      Effective tax rate (%)

      34.4

      2.8


      Net debt

      2,556

      2,215


      Workforce (headcount)

      28,214

      29,301


      3 Represents the figures on an IFRS basis, including the Firmenich results as of the merger date May 8, 2023. 

      dsm-firmenich FY 2024 and Q4

      in € millions


      FY 2024

      Pro forma
      FY 2023¹

      % Change


      Q4 2024


      Q4 2023

      % Change

      Sales

      12,799

      12,310

      4

      3,257

      3,112

      5

      Organic sales growth (%)

      6



      7



      Adj. EBITDA

      2,118

      1,777

      19

      601

      439

      37

      Adj. EBITDA margin (%)

      16.5

      14.4


      18.5

      14.1


      1 Represents the figures on a pro forma basis, including the Firmenich results as if the merger had occurred as of the beginning of the year. The pro forma figures represent the results from continuing operations - please also refer to the section Definitions.

      FY 2024

      • Very strong performance in Perfumery & Beauty and Taste, Texture & Health
      • Solid performance on better business conditions in Health, Nutrition & Care through the second half of the year
      • Significant step-up in financial results in Animal Nutrition & Health

      Business conditions markedly improved during the year. Perfumery & Beauty and Taste, Texture & Health saw very strong demand throughout the year. Health, Nutrition & Care saw business momentum improving in the second half of the year with demand for Dietary Supplements and Early Life Nutrition picking up. Animal Nutrition & Health delivered a strong performance owing to continued strong demand for Performance Solutions throughout the year, together with the normalization of vitamin profitability during the second half of the year. In addition, in Q4 the business benefited from the additional temporary vitamin price effect related to a supply disruption in the vitamin market.

      Adjusted EBITDA was up 19% owing to the good organic sales growth, and the contributions from the synergies, the vitamin transformation program and the temporary vitamin price effect in Q4. The Adjusted EBITDA includes a negative foreign exchange effect estimated at €50 million.

      In 2024, synergies contributed around €105 million to Adjusted EBITDA, predominantly cost-led. The revenues from the sales synergies accounted for about €50 million in 2024. In 2025, the company expects an additional €100 million Adjusted EBITDA contribution from cost and sales synergies.

      Adjusted gross operating free cash flow amounted to €1,552 million, up 55% from the prior period, driven by Adjusted EBITDA growth and operating working capital discipline.

      Q4 2024

      • Good performance in Perfumery & Beauty and Taste, Texture & Health
      • Better performance in Health, Nutrition & Care on improved business conditions
      • Strong performance in Animal Nutrition & Health on better underlying business conditions, further enhanced by the temporary vitamin price effect

      Both Perfumery & Beauty and Taste, Texture & Health delivered a good result in Q4 which is seasonally a low quarter in the year. Health, Nutrition & Care had a good performance, with strong results in i-Health and Biomedical, and improving demand for Dietary Supplements and Early Life Nutrition. Animal Nutrition & Health saw continued strength in Performance Solutions and ongoing improvement in the overall business conditions with improving vitamin profitability. In addition, it benefited from a temporary vitamin price effect.

      Adjusted EBITDA was up 37% owing to a very good organic sales growth, the year-on-year contribution of about €45 million from the vitamin transformation program and synergies and about €85 million from the temporary vitamin price effect in Animal Nutrition & Health, partially offset by a negative foreign exchange effect estimated at €10 million. The resulting Adjusted EBITDA margin was 18.5%.

      Business Unit Review

      Perfumery & Beauty

      Perfumery & Beauty (P&B) is a leading creation and innovation partner for the most iconic global and local brands in consumer goods, lifestyle, and luxury beauty. The business unit is home to some of the best talent in the industry, boasts an unmatched palette of ingredients including captives, and is supported by a vertically integrated supply chain. Powered by our science-based innovations in Fragrance and Beauty & Care, we make our customers' products more desirable, essential, and sustainable, driving consumers' preference.

      Business unit results

      in € millions


      FY 2024

      Pro forma
      FY 2023¹

      % Change


      Q4 2024


      Q4 2023

      % Change

      Sales

      3,964

      3,709

      7

      966

      914

      6

      Organic sales growth (%)

      7



      5



      Adj. EBITDA

      882

      783

      13

      202

      192

      5

      Adj. EBITDA margin (%)

      22.3

      21.1


      20.9

      21.0


      1 Represents the figures on a pro forma basis, including the Firmenich results as if the merger had occurred as of the beginning of the year. The pro forma figures represent the results from continuing operations - please also refer to the section Definitions.

      FY 2024

      Perfumery & Beauty delivered a very strong performance with 9% volume growth, driven by both global and regional accounts. The 2% negative pricing reflected lower input costs. Perfumery had an excellent year with strong organic sales growth in both Fine Fragrances and Consumer Fragrances. These activities benefitted from the continued good demand for differentiated and exclusive fragrance creations and from innovation delivering product superiority. Ingredients' performance was very strong. Beauty & Care delivered a good first half which was followed by a softer half especially due to weak demand for suncare.

      The strong results were supported by innovation in Perfumery, enabling the creation of superior consumer experiences and securing strong win rates, as well as new products launches in Ingredients and Beauty & Care.

      • Perfumery leveraged its strong innovation portfolio, accelerating its adoption in customer briefs and expanding it with new launches. Perfumery demonstrated its innovation leadership with, among others:
        • HALOSCENT® Berry Boost, biodegradable pro-fragrances, enhancing the berry character of a fragrance in laundry care and hair care,
        • HALOSCENT® Pure You, the first pro-fragrance which provides a personalized scent signal uniquely tailored by the microbiome.
        • Upgraded versions of the recently launched POPSCENT® Eco technologies, industry pioneering bio-degradable capsules with continuously improved performance.
      • Ingredients continued to expand its manufacturing footprint with a strong focus on Fragrance Specialties including several iconic products such as HABANOLIDE®, biodegradable musks as well as on pine-based, renewable Industrial Specialties. The business also continues to increase its naturals green extraction capabilities with a new Supercritical Fluid Extraction plant in India and to roll out its unique Ingredients collection on the market through its Sharing Innovation program.
      • Beauty & Care continued to address the importance of suncare and launched Sunsense3, which adds daily indulgence to sun protection by adding fragrances in sun protection. ETERWELL™ YOUTH, powered by Senolytics Science, won five awards, including the Gold Award in Innovation for Best Active Ingredient at the in-Cosmetics Global Summit held in Paris.

      Adjusted EBITDA was up 13% from the prior year, driven by strong innovation-driven volume growth, with the contribution synergies, resulting in a margin of 22.3%.

      Q4 2024

      Perfumery & Beauty delivered a good performance with 5% volume growth. Perfumery delivered a strong volume growth on strong demand for Fine Fragrances and good demand for Consumer Fragrances. Beauty & Care had a soft quarter especially owing to low demand for suncare. Ingredients had a strong quarter.

      Adjusted EBITDA was up 5% from the prior year, primarily driven by good organic sales growth. The Adjusted EBITDA margin reflects the usual seasonality in the fourth quarter.

      Taste, Texture & Health

      Taste, Texture & Health (TTH) brings progress to life by tackling some of society's biggest challenges: providing nutritious, healthy and sustainable food and beverage solutions, accelerating the diet transformation with appealing taste and texture, and nourishing a growing global population whilst minimizing food loss and waste. TTH consists of Taste, which includes flavors, natural extracts, sugar reduction solutions, and Ingredients Solutions, which includes food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins.

      Business unit results

      in € millions


      FY 2024

      Pro forma
      FY 2023¹

      % Change


      Q4 2024


      Q4 2023

      % Change

      Sales

      3,245

      3,038

      7

      790

      768

      3

      Organic sales growth (%)

      8



      4



      Adj. EBITDA

      615

      556

      11

      144

      133

      8

      Adj. EBITDA margin (%)

      19.0

      18.3


      18.2

      17.3


      1 Represents the figures on a pro forma basis, including the Firmenich results as if the merger had occurred as of the beginning of the year. The pro forma figures represent the results from continuing operations - please also refer to the section Definitions.

      FY 2024

      Taste, Texture & Health delivered a very strong performance with 9% volume growth, with both Taste and Ingredients Solutions contributing equally. The strong demand was driven predominantly by regional and local accounts, which was also partly bolstered by a catch-up effect after destocking last year. Sales synergies saw a good momentum, through cross-selling, concept selling and capability sharing, resulting in a steadily growing pipeline in line with our mid-term ambitions.

      Throughout the year, the business created new concepts which were successfully launched across multiple platforms driven by strong interest from customers. Examples included:

      • In Plant-based solutions for dairy applications, the teams developed a solution for oat and soy drinks that combines a gellan gum texturizing agent to improve the mouthfeel and features a new flavor solution to achieve an authentic dairy taste.
      • In Savory, the business created a plant-based tuna solution by bringing together deep expertise in biotechnology, proteins, texturizing agents, taste, and nutrition fortification. The product includes Vertis™ proteins, algae-derived life's®OMEGA, color solutions as well as taste solutions for an authentic tuna flavor.
      • In Dairy, a renowned US dairy company launched new fruit-flavored low-sugar yogurts in different formats that combine TasteGEM® and TastePRINT® flavor solutions together with stevia sweeteners, cultures and enzymes.
      • The business launched several initiatives to digitalize the recipe and product development process, from creation to application, accelerating time-to-market and increasing commercial success. Global application specialists can now easily collaborate across segments and across regions and further expand data- and AI-guided recipe creation and optimization.

      The yeast extracts business was sold to Lesaffre in October 2024. Taste, Texture & Health will continue to supply yeast extracts to Lesaffre under a co-manufacturing agreement until the end of 2025.

      Adjusted EBITDA was up 11%, driven by strong volume growth and the contribution from the synergies, resulting in an Adjusted EBITDA margin of 19%.

      Q4 2024

      Business momentum remained strong throughout the quarter. The reported 4% volume growth followed an exceptionally strong third quarter with 13% volume growth.

      Adjusted EBITDA was up 8% on higher volumes, the contribution from the synergies and reflecting the deconsolidation of the yeast extracts business. The Adjusted EBITDA margin was 18.2%

      Health, Nutrition & Care

      Health, Nutrition & Care (HNC) enables people to improve their health by supplementing their diet with critical nutrients and driving medical innovation forward, so helping to optimize immunity, speed up recovery and enhancing quality of life.

      Business unit results

      in € millions


      FY 2024

      Pro forma
      FY 2023¹

      % Change


      Q4 2024


      Q4 2023

      % Change

      Sales

      2,214

      2,270

      (2)

      562

      581

      (3)

      Organic sales growth (%)

      1



      5



      Adj. EBITDA

      371

      389

      (5)

      102

      94

      9

      Adj. EBITDA margin (%)

      16.8

      17.1


      18.1

      16.2


      1 Represents the figures on a pro forma basis, including the Firmenich results as if the merger had occurred as of the beginning of the year. The pro forma figures represent the results from continuing operations - please also refer to the section Definitions.

      FY 2024

      Health, Nutrition & Care delivered 2% volume growth during the year. Medical Nutrition, i-Health, and Biomedical performed well throughout the period. Dietary Supplements and Early Life Nutrition improved during the second half of the year, driving 5% volume growth in the period for the business unit, owing to good demand for algal omega-3 oils and Early Life Nutrition premix and HMOs.

      Health, Nutrition & Care launched several new specialized, preventative health solutions:

      • Unlocking Health from the Gut: focusing on the restoration and support of the human gut ecosystem, the business launched Humiome® Post LB, a pioneering postbiotic, to improve gut wellbeing, and the first ever vitamin that acts as a biotic, Humiome® B2, with patented Microbiome Targeted Technology™ (MTT™), delivering 90% of vitamin B2 directly to the gut microbiome in the colon. These innovations have the potential to elevate gut health, but also immunity, mental well-being, and healthy aging.
      • Increasing Health Expectancy: focusing on reducing the 10-year gap between lifespan and health span, Health, Nutrition & Care took an innovative approach offering solutions made of algal lipids, biotics, and the best nutritional ingredients that act at cellular level. These include resVida® (99% pure resveratrol), a powerful senomorphic and antioxidant, ALL Q® (CoQ10 Ubiquinone), an essential coenzyme for maintaining cell energy levels, and the super antioxidant Redivivo® (Lycopene), a bioactive form of lycopene, which helps regulate the body's processes responsible for producing inflammatory substances.
      • Supporting the Big Shift to Algal: within the life's®OMEGA algal lipids range, which offers clean, potent, unlimited, and sustainable lipids, the business developed life's®OMEGA O3020, the first algal-based lipid with high EPA content, available in Europe and the USA.
      • HMOs: obtained regulatory approval in over 170 countries. With now 7 HMOs commercially available, of which 2 already approved in the Chinese market and several in the regulatory approval pipeline, the business moved to sign supply contracts with major global and domestic brands. Additionally, the business extended its infant nutrition offerings with a strategic partnership with Lallemand to allow customers access to unique combinations of HMOs and probiotics. Further developments in speciality proteins have also been shaped for infant nutrition.

      The reported Adjusted EBITDA was down 5% from the previous year. Corrected for the negative foreign exchange effect and the divestment of the marine lipids activities (-10%), the underlying Adjusted EBITDA growth was up 5%.

      Q4 2024

      Health, Nutrition & Care had a good quarter with 5% volume growth. I-Health and Biomedical performed well, while the business saw further improvement in demand for Dietary Supplements, especially in algal lipid solutions, and Early Life Nutrition, with the latter benefitting from higher HMOs and premix sales.

      Adjusted EBITDA was up 9% from the previous year period. Corrected for the negative foreign exchange effect and the divestment of the marine lipids activities (-15%), the underlying Adjusted EBITDA growth was up 24%. The Adjusted EBITDA margin was up to 18.1%.

      Animal Nutrition & Health

      Animal Nutrition & Health (ANH) helps delivering healthy animal proteins efficiently and sustainably, whilst harnessing the power of data to make animal farming practices more sustainable, productive, and transparent.

      Business unit results

      in € millions


      FY 2024

      Pro forma
      FY 2023¹

      % Change


      Q4 2024


      Q4 2023

      % Change

      Sales

      3,324

      3,227

      3

      930

      833

      12

      Organic sales growth (%)

      5



      16



      Adj. EBITDA

      343

      128

      168

      176

      32

      450

      Adj. EBITDA margin (%)

      10.3

      4.0


      18.9

      3.8


      1 Represents the figures on a pro forma basis, including the Firmenich results as if the merger had occurred as of the beginning of the year. The pro forma figures represent the results from continuing operations - please also refer to the section Definitions.

      FY 2024

      Animal Nutrition & Health delivered a strongly improved performance versus the previous year with 5% organic sales growth, with 3% volume growth and prices up 2%.

      Performance Solutions delivered strong results throughout the year, especially in mycotoxin risk management products that are now offered together with precision service complementary offerings through the premix network. Bovaer® and Veramaris® had an excellent year. In the second half of the year, demand for Essential Products increased as farmer economics improved and vitamin profitability started to normalize, highlighting the quality of the underlying business. In addition, in Q4 the business benefited from the additional temporary vitamin price effect from vitamins A and E related to a supply disruption in the vitamin market.

      In 2024, Animal Nutrition & Health launched several innovations and expanded its Performance Solutions and Precision Services reach across species and geographies:

      • The feed enzymes HiPhorius and ProAct360 help increase efficiency and lower the carbon footprint of animal protein production and are available now across several geographies.
      • Verax DBS is a newly developed commercially available precision service that helps farmers by exposing vitamin D deficiencies in farmed animals (poultry and swine).

      Adjusted EBITDA was up significantly from the previous year, owing to good organic sales growth, the contributions from the vitamin transformation program and the temporary vitamin price effect in Q4.

      Q4 2024

      Animal Nutrition & Health delivered a strongly improved performance, led by prices up 15%, owing to a further normalization of the vitamin prices and the temporary vitamin price effect.

      Adjusted EBITDA was up significantly from the previous year period, owing to good organic sales growth, the contribution from the vitamin transformation program, and a €85 million benefit from the temporary vitamin price effect. The Adjusted EBITDA margin increased to 18.9%.

      Corporate activities

      in € millions


      FY 2024

      Pro forma
      FY 2023¹

      % Change


      Q4 2024


      Q4 2023

      % Change

      Sales

      52

      66

      (21)

      9

      16

      (44)

      Adj. EBITDA

      (93)

      (79)

      (18)

      (23)

      (12)

      (92)

      1 Represents the figures on a pro forma basis, including the Firmenich results as if the merger had occurred as of the beginning of the year. The pro forma figures represent the results from continuing operations - please also refer to the section Definitions.

      Cash Flow and Working Capital

      Cash Flow and Working Capital

       in € millions


      FY 2024

      Pro forma
      FY 2023¹

      Adj. gross operating free cash flow

      1,552

      999

      Sales to cash conversion %

      12.1

      8.1




      Operating working capital (OWC)

      3,603

      3,769²

      OWC as % of sales - end of period

      27.7

      30.3

      Total working capital (WC)

      2,734

      3,198

      Total WC as % of sales - end of period

      21.0

      25.7

      1 Represents the figures on a pro forma basis, including the Firmenich results as if the merger had occurred as of the beginning of the year. The pro forma figures represent the results from continuing operations - please also refer to the section Definitions.

      2 Restated for comparative purposes.

      The adjusted gross operating free cash flow was up €553 million versus prior year, representing a cash conversion of 12% on Sales.

      OWC improved to 27.7% of Sales from 30.3% in prior year, reflecting discipline in managing operational efficiency and continued commitment to progress on our cash ambition.

      Alternative Performance Measures (APMs)

      The main APM adjustments in 2024 were:

      • Acquisition (merger), divestment, and integration costs of €40 million, mainly related to the merger transaction, the divestment of the yeast extracts business, the sale of the Jiangshan vitamin C business, and the preparation for the Animal Nutrition & Health business carveout.
      • Restructuring costs of €45 million, mainly related to the vitamin transformation program.
      • Impairments of Property, Plant and Equipment (PPE), goodwill and intangible assets of €238 million, mainly related to the divestments of the marine lipids business (€76 million) and the yeast extracts business (€73 million) and other impairments following the portfolio tuning (€89 million).

      A reconciliation between the APMs and the most directly reconcilable IFRS metric can be found on page 18 of this press release.

      Sustainability

      The world is in flux on many fronts with an accelerated pace, and in this context dsm-firmenich stays the course in its commitment to bring progress to life. Sustainability permeates everything dsm-firmenich does, driving progress for both People and Planet.

      In 2024, the company made major strides in its sustainability journey. dsm-firmenich's mid-term and long-term targets for reducing greenhouse gas emissions were validated by the Science Based Targets initiative (SBTi), the leading authority on certifying corporate climate goals. By focusing on climate mitigation activities in its own operations and value chain, dsm-firmenich aims to reduce its greenhouse gas emissions to net-zero by 2045.

      Looking ahead, dsm-firmenich remains dedicated to leveraging science and innovation to create solutions that meet the needs of people and the planet — because the world needs it now more than ever.

      People

      dsm-firmenich made progress on improving the health, well-being, and livelihoods of employees and people around the world.


      2024

      2023

      Safety Total recordable incident rate

      0.24

      0.31

      Employee engagement

      79 %

      80% 1

      Inclusion

      67 %

      -

      Gender pay equity

       ✓   

      -

      Pay living wage to our employees

      ✓ 

      -

      1. Result of EES survey in January 2024. 

      The safety and health of employees and the communities the company serves are top priorities for dsm-firmenich. In 2024, the company achieved a significant reduction in safety incidents, thanks to the increased ownership of safety by all employees. A first wave of Life Saving Rules and new Safety, Health and Environment (SHE) requirements was rolled out during the year.

      In 2024, the company launched its human rights policy, published its first human rights report and conducted an analysis on human rights gaps in its own operations. An action plan to address the gaps is currently in process.

      The results from Employee Engagement and Inclusion surveys remained strong, with 85% of employees stating they feel their work is meaningful to them, and an overall engagement score of 79%. dsm-firmenich continued to invest in upskilling employees with a newly launched learning platform as well as dedicated mentoring programs.

      dsm-firmenich continues to promote nutrition for those most in need, reaching 620 million beneficiaries with high-quality nutritional intervention solutions. In 2024, dsm-firmenich renewed its partnership with the United Nations World Food Programme (WFP), reaching 38 million people with nutritious food products enhanced by the partnership, and a further 20.5 million people through WFP country programs, including fortified rice initiatives.

      Planet

      dsm-firmenich views climate and nature as deeply interconnected, requiring a comprehensive and integrated approach. The company is committed to developing solutions that address both climate change and the preservation and restoration of natural ecosystems simultaneously.


      Target

      2024

      2023

      Greenhouse gas emissions




      Scope 1 and 2

      42% reduction by 2030

      27 %

      -

      Scope 3

      25% reduction by 2030

      20 %

      -

      Purchased electricity from renewable resources

      100% in 2025

      95 %

      88 %





      In Climate, dsm-firmenich developed its first Climate Transition Action Plan (CTAP) in 2024 to create a clear roadmap towards its near-term and long-term net-zero targets.

      In 2024 the company achieved significant results:

      • 28% reduction in Scope 1 & 2 vs. the 2021 baseline
      • 19% reduction in Scope 3 vs. the 2021 baseline
      • 95% of electricity from renewable sources

      The company is on track to achieve 100% of annual sourcing of purchased renewable electricity in 2025 and maintain that level through 2030.

      To reduce Scope 3 emissions, the company is actively engaging with suppliers through its Responsible Sourcing Framework and the 'Joining Forces for NetZero' program to drive collaborative decarbonization efforts.

      In Nature, dsm-firmenich focuses on water stewardship, biodiversity management, and resource efficiency.

      The company also supports a wide range of biodiversity programs in the communities where it operates, including mangrove restoration in Indonesia, biodiversity projects in India, and marshland restoration in New Jersey.

      Governance

      As a combined, merged company, dsm-firmenich has made substantial strides in elevating its governance to the highest level.

      In 2024, the company issued numerous policies and position papers that enhanced its good governance practices. These documents covered critical areas such as Protecting Forests and Land-based Natural Ecosystems, Safeguarding Biodiversity, and Combating Modern Slavery, among others.

      dsm-firmenich launched a series of mandatory training programs designed to ensure company-wide adoption and adherence to the company's Code of Business Ethics, equipping all employees to uphold these standards.

      Definitions

      This press release includes information that is presented in accordance with IFRS as issued by the International Accounting Standard Board and alternative performance measures (APMs). Please refer to the section below for the definitions as applied. The comparatives in the management report to this press release contain information that is presented on a pro forma basis ('pro forma'), which includes the Firmenich results as if the merger had occurred on January 1, 2022. The pro forma figures represent the results from continuing operations – please also refer to the Integrated Annual Report 2023.

      Alternative Performance Measures (APMs)

      In monitoring the financial performance of dsm-firmenich, management uses certain Alternative performance measures (APMs) not defined by IFRS. These APMs should not be viewed in isolation as alternatives to the equivalent IFRS measures and should be used as supplementary information in conjunction with the most directly comparable IFRS measures. APMs do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other companies.

      To arrive at the Alternative Performance Measures (APMs) Adjusted EBITDA, Adjusted EBIT, and Adjusted net profit, adjustments are made for material items of income and expense arising from circumstances such as acquisitions and divestments, restructuring, impairments and other events (i.e., APM adjustments). Other APM adjusting events include site closure costs, environmental cleaning, litigation settlements or other non-operational (contractual) arrangements. Other than items related to acquisition and integration costs incurred in the first year from the acquisition date (including non-recurring inventory value adjustments) as well as adjustments due to previously recognized APM adjusting events, the threshold is €10 million.

      The APMs used throughout this press release are:

      Organic sales growth (OSG)

      Organic sales growth is the sales growth excluding the impact of acquisitions, divestments, and currency impacts.

      Earnings before interest, tax, depreciation and amortization (EBITDA) 

      EBITDA is defined as IFRS metric operating profit plus depreciation, amortization, and impairments.

      Adjusted earnings before interest, tax, depreciation and amortization (Adj. EBITDA) 

      Adjusted EBITDA is the EBITDA adjusted for material items of profit or loss, as defined under 'APM adjustments'.

      EBITDA margin

      EBITDA margin is EBITDA expressed as a percentage of net sales.

      Adjusted EBITDA margin (Adj. EBITDA margin)

      Adjusted EBITDA margin is adjusted EBITDA expressed as a percentage of net sales.

      Adjusted operating profit (Adj. EBIT)

      Adjusted operating profit (Adj. EBIT) is the IFRS metric operating profit adjusted for material items of profit or loss, as defined under 'APM adjustments'.

      Core adjusted EBIT (Core adj. EBIT)

      Core adjusted EBIT is calculated as the IFRS metric operating profit adjusted for material items of profit or loss, as defined under 'APM adjustments', and adjusted for the impact of the Firmenich purchase price allocation (PPA).

      Adjusted net profit (Adj. net profit)

      Adjusted net profit is the IFRS metric net profit adjusted for material items of profit or loss, as defined under 'APM adjustments'.

      Core adjusted net profit (Core adj. net profit)

      Core adjusted net profit is the IFRS metric net profit (from continuing operations) adjusted for material items of profit or loss, as defined under 'APM adjustments', and adjusted for the impact of the Firmenich purchase price allocation (PPA).

      Adjusted gross operating free cash flow (AGOFCF)

      Adjusted gross operating free cash flow (AGOFCF) is defined as the IFRS metric operating profit plus depreciation, amortization, and impairments, adjusted for material items of profit or loss, as defined under 'APM adjustments', adjusted for intrinsic changes in the working capital, minus capital expenditures. This metric is based on continuing operations.

      Sales to cash conversion %

      Sales to cash conversion % is the adjusted gross operating free cash flow (AGOFCF) as a percentage of net sales.

      Adjusted earnings per share (Adj. EPS)

      Adjusted earnings per share (Adjusted EPS) is calculated as the net profit available to holders of ordinary shares adjusted for material items of profit or loss, as defined under 'APM adjustments', divided by the average number of ordinary shares outstanding.

      Core adjusted earnings per share (Core adj. EPS)

      Core adjusted earnings per share (Core adjusted EPS) is calculated as the net profit (from continuing operations) available to holders of ordinary shares adjusted for material items of profit or loss, as defined under 'APM adjustments', and adjusted for the impact of the Firmenich purchase price allocation (PPA), divided by the average number of ordinary shares outstanding.

      Capital employed

      Capital employed is the total of the carrying amount of intangible assets and property, plant and equipment, inventories, trade receivables and other receivables, less trade payables, other current liabilities, investment grants and customer funding. Average capital employed is calculated as the average of the capital employed at the end of the preceding five quarters, including the current quarter.

      Core capital employed

      Core capital employed is defined as capital employed, adjusted for the impact of the Firmenich purchase price allocation (PPA). Average core capital employed is calculated as the average of the core capital employed at the end of the preceding five quarters, including the current quarter.

      Return on capital employed (ROCE)

      Return on capital employed (ROCE) is the adjusted operating profit (from continuing operations) as a percentage of average capital employed.

      Core adjusted return on capital employed (Core adj. ROCE)

      Core adjusted return on capital employed (Core adj. ROCE) is core adjusted EBIT as a percentage of average core capital employed.

      Operating working capital (OWC)

      The total of inventories and trade receivables, less trade payables.

      Operating working capital (OWC) as % of sales

      Operating working capital as % of sales is the operating working capital as a percentage of annualized fourth-quarter net sales.

      Working capital (WC)

      The total of inventories and current receivables, less current payables.

      Working capital (WC) as % of sales

      Working capital as % of sales is the working capital as a percentage of annualized fourth-quarter net sales.

      Capital expenditures (CAPEX)

      Capital expenditures include all investments in intangible assets and property, plant and equipment.

      Net debt

      Net debt is the total of current and non-current borrowings less cash and cash equivalents, current investments and the net position of derivatives.

      Condensed consolidated financial statements 2024

      Condensed consolidated income statement


      FY 2024

      FY 2023

      Continuing operations



      Net sales

      12,799

      10,627

      Gross profit

      4,245

      2,611

      Operating profit

      561

      (497)

      Financial income and expense

      (134)

      (150)

      Profit before tax

      427

      (647)

      Income tax expense

      (147)

      18

      Share of net profit of associates and joint ventures

      -

      (7)

      Net profit from continuing operations

      280

      (636)

      Net profit from discontinued operations

      -

      2,789

      Net profit for the period

      280

      2,153

      Attributable to: 



      - Holders of shares

      250

      2,131

      - Non-controlling interests

      30

      16

      - Dividend on cumulative preference shares

      -

      6




      Earnings per share (EPS) total (in €):



      - Basic EPS

      0.94

      9.14




      Earnings per share (EPS) continuing operations (in €):



      - Basic EPS

      0.94

      (2.82)

      Condensed consolidated balance sheet

      in € millions

      December 31

      2024

      December 31

      2023

      Assets



      Goodwill and intangible assets

      18,078

      18,738

      Property, plant and equipment

      5,725

      5,549

      Deferred tax assets

      299

      228

      Share in associates and joint ventures

      342

      130

      Derivatives

      51

      46

      Other non-current assets

      453

      735

      Non-current assets

      24,948

      25,426

      Inventories

      3,290

      3,390

      Trade receivables

      2,589

      2,553

      Income tax receivables

      51

      107

      Other receivables

      129

      183

      Derivatives

      23

      42

      Financial investments

      50

      107

      Cash and cash equivalents

      2,667

      2,456

      Sub-total

      8,799

      8,838

      Assets held for sale

      -

      6

      Current assets

      8,799

      8,844

      Total assets

      33,747

      34,270




      Equity and liabilities



      Shareholders' equity

      22,511

      22,908

      Non-controlling interest

      186

      162

      Equity

      22,697

      23,070

      Deferred tax liabilities

      1,556

      1,751

      Employee benefit liabilities

      487

      520

      Provisions

      87

      142

      Borrowings

      4,444

      4,114

      Derivatives

      7

      8

      Other non-current liabilities

      109

      146

      Non-current liabilities

      6,690

      6,681

      Employee benefit liabilities

      62

      49

      Provisions

      77

      34

      Borrowings

      836

      716

      Derivatives

      60

      28

      Trade payables

      2,276

       2,174¹ 

      Income tax payables

      223

      177

      Other current liabilities

      826

       1,333¹ 

      Sub-total

      4,360

      4,511

      Liabilities held for sale

      -

      8

      Current liabilities

      4,360

      4,519

      Total equity and liabilities

      33,747

      34,270

      1 Restated for comparative purposes.

      Condensed consolidated cash flow statement

      in € millions

      FY 2024

      FY 2023

      Cash and cash equivalents (at beginning of period)

      2,456

      2,755

      Operating activities



      EBITDA

      1,991

      3,637

      Changes in working capital

      198

      160

      Income tax

      (275)

      (179)

      Result divestments

      (47)

      (2,845)

      Other

      (89)

      492

      Cash provided by operating activities

      1,778

      1,265

      Investing activities



      Payments for intangible assets and property, plant and equipment

      (764)

      (684)

      Acquisition of subsidiaries

      (5)

      (3,691)

      Disposal of subsidiaries

      42

      3,533

      Proceeds from disposal of other non-current assets

      416

      16

      Change in short-term financial investments

      43

      45

      Interest received

      33

      60

      Dividend received and capital (re)payments

      6

      (5)

      Other cash from / used in investing activities

      (23)

      -

      Cash used in investing activities

      (252)

      (726)

      Financing activities



      Dividends paid

      (667)

      (582)

      Interest paid

      (67)

      (61)

      Repurchase of shares

      (706)

      (256)

      Proceeds from (re)issued shares

      21

      757

      Proceeds from / repayment of borrowings

      210

      (549)

      Payment of lease liabilities

      (110)

      (73)

      Proceeds from / repayment of debt to credit institutions

      38

      (7)

      Other cash from / used in financing activities

      (53)

      (49)

      Cash (used in) / from financing activities

      (1,334)

      (820)

      Change in cash and cash equivalents

      192

      (281)

      Exchange differences relating to cash held

      19

      (18)

      Cash and cash equivalents at 31 December

      2,667

      2,456

      Reconciliation to Alternative Performance Measures

      in € millions

      FY 2024

      FY 2023

      Operating profit (EBIT)

      561

      (497)

      Depreciation, amortization and impairments

      1,430

      1,307

      EBITDA

      1,991

      810

      Acquisitions/divestments 

      40

      363

      Restructuring 

      45

      234

      Other

      42

      36

      Sub-total APM adjustments to EBITDA

      127

      633

      Adj. EBITDA

      2,118

      1,443




      Operating profit (EBIT)

      561

      (497)

      APM adjustments to EBITDA

      127

      633

      Impairments of PPE and Intangible assets

      238

      294

      Sub-total APM adjustments to operating profit (EBIT)

      365

      927

      Adj. operating profit (EBIT)

      926

      430

      PPA adjustments dsm-firmenich

      287

      184

      Core adj. operating profit (EBIT)

      1,213

      614




      Net profit from continuing operations

      280

      (636)

      APM adjustments to operating profit (EBIT)

      365

      927

      APM adjustments to financial income and expense 

      5

      34

      Income tax related to APM adjustments

      (45)

      (135)

      APM adjustments to share of the profit of associates/jointly controlled entities

      (4)

      -

      Sub-total APM adjustments

      321

      826

      Adj. Net profit continuing operations

      601

      190

      PPA adjustments dsm-firmenich

      248

      190

      Core adj. net profit continuing operations 

      849

      380

      Profit attributable to non-controlling interests

      (30)

      (16)

      Dividend on Cumulative Preference Shares

      -

      (6)

      Core adj. net profit continuing operations available to holders of ordinary shares

      819

      358

      The main APM adjustments in 2024 were:

      • Acquisition (merger), divestment, and integration costs of €40 million, mainly related to the merger transaction, the divestment of the yeast extracts business, the sale of the Jiangshan vitamin C business, and the preparation for the Animal Nutrition & Health business carveout.
      • Restructuring costs of €45 million, mainly related to the vitamin transformation program.
      • Impairments of Property, Plant and Equipment (PPE), goodwill and intangible assets of €238 million, mainly related to the divestments of the marine lipids business and the yeast extracts business and some other small impairments following the portfolio tuning.

      2024

      2023


       Continuing
      operations 

       Total
        

       Continuing
      operations 

       Total
        

      Earnings per share (EPS)





      Average number of ordinary shares outstanding (x million)

      264.6

      264.6

      233.2

      233.2






      x € million





      Net profit available to holders of ordinary shares

      250

      250

      (658)

      2,131

      Adjusted net profit available to holders of ordinary shares

      571

      571

      168

      161

      Core adj. net profit available to holders of ordinary shares

      819

      819

      358

      351






      in €





      EPS

      0.94

      0.94

      (2.82)

      9.14

      Adj. EPS

      2.16

      2.16

      0.72

      0.69

      Core adj. EPS

      3.10

      3.10

      1.54

      1.51


      2024

      2023

      Adjusted EBITDA

      2,118

      1,441

      Change working capital, total group

      198

      160

      Capital expenditures, total group

      (764)

      (692)

      Excluding discontinued operations

      -

      (53)

      Adj. gross operating free cash flow                                                                        

      1,552

      856

      Net sales

      12,799

      10,627

      Sales to cash conversion %

      12.1

      8.1

      Geographical information


      Switzer-
      land

      Nether-
      lands

      Rest of
      EMEA

      North
      America

      Latin
      America

      China

      Rest of
      Asia

      Total

      FY 2024









      Net sales (by destination)









      In € millions

      214

      420

      3,938

      2,928

      1,887

      1,096

      2,316

      12,799

      In %

      2

      3

      30

      23

      15

      9

      18

      100










      Workforce at period-end (headcount)

      3,734

      1,776

      8,134

      4,155

      3,565

      3,365

      3,485

      28,214

      Intangible assets and property, plant and
      equipment at period-end (carrying amount)

      14,946

      1,618

      3,220

      2,689

      428

      603

      299

      23,803










      FY2023









      Net sales (by destination)









      In € millions

      204

      424

      3,103

      2,420

      1,653

      997

      1,826

      10,627

      In %

      2

      4

      29

      23

      16

      9

      17

      100










      Workforce at year-end (headcount)

      3,647

      1,783

      7,953

      4,264

      3,617

      4,664

      3,373

      29,301

      Intangible assets and property, plant and
      equipment at year-end (carrying amount)

      15,474

      1,665

      3,147

      2,600

      506

      612

      283

      24,287

      Notes to the Condensed consolidated financial statements

      The financial statements and other reported data in this press release have not been audited.

      Financial calendar

      March 25, 2025 – ESG expert investor event
      April 30, 2025 – publication of dsm-firmenich Q1 2025 trading update
      May 6, 2025 - AGM
      July 31, 2025 - publication of dsm-firmenich H1 2025 results
      October 30, 2025 - publication of dsm-firmenich Q3 2025 trading update

      Additional information

      Today dsm-firmenich will hold a webcast for investors and analysts at 9:00 am CET. Details on how to access this call can be found on www.dsm-firmenich.com.

      For more information

      Media relations 
      Robin Roothans
      tel. +41 (0)79 280 03 96
      e-mail media@dsm-firmenich.com 

      Investor relations
      Dave Huizing
      tel. +31 (0)88 425 7306
      e-mail investors@dsm-firmenich.com

      About dsm-firmenich

      As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world's growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss-Dutch company, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life™ every day, everywhere, for billions of people.
      www.dsm-firmenich.com

      Forward-looking statements
      This press release may contain forward-looking statements with respect to dsm-firmenich's future performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance, transaction progress and positions to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The English language version of this press release prevails over other language versions.

      PDF - https://mma.prnewswire.com/media/2619144/Presentation_to_Investors_dsm_firmenich_FY_2024_FINAL.pdf
      Logo - https://mma.prnewswire.com/media/2071772/5165550/dsm_firmenich_Logo.jpg

      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.